Skip to main content

Clinical Trials Using Paclitaxel

Review the clinical trials studying paclitaxel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 199

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Status: Active
Location: 4 locations
Papaverine in Combination with Chemoradiation for the Treatment of Stage II, III, or IV Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Immunosensitizing Radiation with Neoadjuvant Chemoimmunotherapy for the Treatment of Patients with Stage II-IIIC Borderline Resectable Non-Small Cell Lung Cancer, The NeoRADjuvant Trial
Status: Active
Location: 2 locations
Implantable Microdevice for Evaluating Drug Responses in Patients with Head and Neck Cancers, the Window of Opportunity Study
Status: Active
Location: 2 locations
Paclitaxel before Surgery in Treating Patients with Breast Cancer
Status: Active
Location: 2 locations
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Perioperative Intraperitoneal Paclitaxel for the Treatment of Stage IV Gastric or Gastroesophageal Adenocarcinoma with Carcinomatosis or Positive Cytology
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Chemotherapy with or without HCW9218 before Surgery for the Treatment of Stage III-IV High Grade Serous Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Pulsed Dose Chemotherapy Plus Pembrolizumab for First Line Treatment of Recurrent or Metastatic HNSCC
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Gastric Cancer with Limited Peritoneal Metastasis, ROBO-CHIP Study
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy before Surgery for the Treatment of Patients with Breast Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
First Line Chemotherapy (Carboplatin and Paclitaxel) and Immunotherapy (Pembrolizumab) for the Treatment of Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Vitamin D Supplementation for the Improvement of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer
Status: Active
Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina
A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized Treatment following Chemoradiotherapy and Immunotherapy for the Treatment of Stage III Non-small Cell Lung Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Paclitaxel for the Treatment of Patients with Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
A Vaccine (Dendritic Cell 1) for the Treatment of Patients with HER-2 Positive Breast Cancer, NATASHA Study
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Anthracycline-Free Chemotherapy and Immunotherapy Regimen for the Treatment of Triple-Negative Breast Cancer Patients at Risk for Cardiotoxicity, NeoCARD Trial
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Pembrolizumab in Combination with Chemotherapy for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, SINERGY Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsies for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan